Literature DB >> 8006106

High-performance liquid chromatographic assay for the measurement of atovaquone in plasma.

D V DeAngelis1, J D Long, L L Kanics, J L Woolley.   

Abstract

A rapid and efficient isocratic high-performance liquid chromatographic assay for the measurement of atovaquone in plasma has been developed and validated. The drug was extracted from plasma with organic solvents, assayed on a C1 column with a mobile phase of methanol-0.1% acetic acid (70:30, v/v), and detected by ultraviolet absorbance at 254 nm. Recovery of atovaquone from plasma was greater than 85%. Intra- and inter-assay variability were less than 8%, and the average accuracy of the assay (expressed as % bias) ranged from -7.4 to + 2.2%. The upper and lower limits of quantitation were 100 and 0.25 microgram/ml, respectively. Measurement of atovaquone in spiked plasma control samples during routine runs of clinical trial samples confirmed the reliability of the assay.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8006106     DOI: 10.1016/0378-4347(93)e0387-6

Source DB:  PubMed          Journal:  J Chromatogr


  5 in total

1.  Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis.

Authors:  N Schöler; K Krause; O Kayser; R H Müller; K Borner; H Hahn; O Liesenfeld
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women.

Authors:  K Na-Bangchang; C Manyando; R Ruengweerayut; D Kioy; M Mulenga; G B Miller; J Konsil
Journal:  Eur J Clin Pharmacol       Date:  2005-07-23       Impact factor: 2.953

3.  In vitro and in vivo effects of rifabutin alone or combined with atovaquone against Toxoplasma gondii.

Authors:  S Romand; C Della Bruna; R Farinotti; F Derouin
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

4.  Atovaquone maintenance therapy prevents reactivation of toxoplasmic encephalitis in a murine model of reactivated toxoplasmosis.

Authors:  Ildiko R Dunay; Markus M Heimesaat; Faris Nadiem Bushrab; Rainer H Müller; Hartmut Stocker; Keikawus Arasteh; Michael Kurowski; Rudolf Fitzner; Klaus Borner; Oliver Liesenfeld
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

5.  A validated method for development of atovaquone as API and tablet dosage forms by UV spectroscopy.

Authors:  Kalpesh N Patel; Jayvadan K Patel; Manish P Patel; Ganesh C Rajput
Journal:  Pharm Methods       Date:  2010-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.